Evidence map›Paper›PMID 28566368›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2017

Caspofungin Increases Fungal Chitin and Eosinophil and γδ T Cell-Dependent Pathology in Invasive Aspergillosis.

Nansalmaa Amarsaikhan, Ethan M Sands, Anand Shah, Ali Abdolrasouli, Anna Reed, James E Slaven, Darius Armstrong-James, Steven P Templeton

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Survival Factor A (SvfA) Contributes toJournal of fungi (Basel, Switzerland) · 2023
    Article
  5. Chitin Biosynthesis inJournal of fungi (Basel, Switzerland) · 2023
    Review
  6. Living without eosinophils: evidence from mouse and man.The European respiratory journal · 2023
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Eosinophil-Associated Innate IL-17 Response PromotesFrontiers in cellular and infection microbiology · 2018
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Nansalmaa AmarsaikhanDepartment of Microbiology and Immunology, Indiana University School of Medicine-Terre Haute, Terre Haute, IN 47809.
Ethan M SandsDepartment of Microbiology and Immunology, Indiana University School of Medicine-Terre Haute, Terre Haute, IN 47809.
Anand ShahFungal Pathogens Laboratory, National Heart and Lung Institute, Imperial College London, London SW7 2AZ, United Kingdom.
Ali AbdolrasouliFungal Pathogens Laboratory, National Heart and Lung Institute, Imperial College London, London SW7 2AZ, United Kingdom.
Anna ReedLung Transplant Unit, Royal Brompton and Harefield National Health Service Trust, London UB9 6JH, United Kingdom; and.ORCID 0000-0002-7826-9101
James E SlavenDepartment of Biostatistics, Indiana University School of Medicine, Indianapolis, IN 46202.
Darius Armstrong-JamesFungal Pathogens Laboratory, National Heart and Lung Institute, Imperial College London, London SW7 2AZ, United Kingdom.
Steven P TempletonDepartment of Microbiology and Immunology, Indiana University School of Medicine-Terre Haute, Terre Haute, IN 47809; sptemple@iupui.edu.
Indiana University · USLung Institute · USIndiana University – Purdue University Indianapolis · USNational Health Service · GB

Funding

Eosinophil activation in pulmonary aspergillosisR03AI122127 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI TEMPLETON, STEVEN P · 2016 to 2017
$138k
Medical Research Council G0902260Medical Research Council MR/K002708/1NIAID NIH HHS R03 AI122127
6 · The paper itself

Abstract

The polysaccharide-rich fungal cell wall provides pathogen-specific targets for antifungal therapy and distinct molecular patterns that stimulate protective or detrimental host immunity. The echinocandin antifungal caspofungin inhibits synthesis of cell wall β-1,3-glucan and is used for prophylactic therapy in immune-suppressed individuals. However, breakthrough infections with fungal pathogen

Indexed as

AnimalsAntifungal AgentsAspergillus fumigatusBronchoalveolar Lavage FluidCaspofunginChitinEchinocandinsEosinophilsHumansInvasive Pulmonary AspergillosisLipopeptidesMiceReceptors, Antigen, T-Cell, gamma-deltaT-LymphocytesAntifungal AgentsCaspofunginChitinEchinocandinsLipopeptidesReceptors, Antigen, T-Cell, gamma-delta

Identifiers

PMID28566368
PMCPMC5508594
OpenAlexW2618661071

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.